46
Participants
Start Date
June 25, 2021
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
Durvalumab
Durvalumab: 1500 mg iv
carboplatin
Carboplatin: AUC 5 mg/mL/min iv
etoposide
Etoposide: 100 mg/m2 iv
Thoracic radiotherapy
Thoracic radiotherapy: 39 Gy in 13 fractions, starting 3-8 weeks after day 1 of last cycle of induction treatment, over 2.5 weeks Prophylactic cranial irradiation (PCI) is allowed but optional: according to local practice, starting 3-8 weeks after day 1 of last cycle of induction treatment Follow up phase Patients will be followed up for 24 months, every 8 weeks.
Hôpitaux Universitaires de Genève, Geneva
HFR Freiburg - Kantonsspital, Villars-sur-Glâne
Inselspital Bern, Bern
Regionalspital Thun, Thun
Universitaetsspital Basel, Basel
IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona
UniversitätsSpital Zürich, Zurich
Kantonsspital Winterthur, Winterthur
Klinik Hirslanden, Männedorf
Spital Männedorf, Männedorf
Kantonsspital Aarau, Aarau
Kantonsspital Graubuenden, Chur
Kantonsspital Olten, Olten
Kantonsspital - St. Gallen, Sankt Gallen
Swiss Cancer Institute
OTHER